Stay updated on PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.

Latest updates to the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page
- ChecktodayChange DetectedThe page now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates an administrative update to the page's revision history.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA new publication citation is added to the Publications section, reporting Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in PD-L1-unselected, metastatic NSCLC. The publication record is updated to Revision: v3.5.4, replacing the prior v3.5.3 entry.SummaryDifference0.1%

- Check43 days agoChange DetectedThe page’s displayed revision version was incremented from **v3.5.2** to **v3.5.3**, reflecting a site/version update without altering the study details shown.SummaryDifference0.0%

- Check50 days agoChange DetectedThe Spartalizumab publication citation was updated to Revision: v3.5.2 with an erratum added, replacing the previous Revision: v3.5.0.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 on the page.SummaryDifference0.0%

- Check86 days agoChange DetectedRevision history updated: added Revision: v3.4.3 and removed Revision: v3.4.2.SummaryDifference0.0%

Stay in the know with updates to PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PDR001 with Chemo and Immunology Agents in NSCLC Clinical Trial page.